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Conclusions: The target volume coverage and the normal tissue doses 
in patients with prostate cancer were compared between the 3 
treatment plans, using VERO, TomoTherapy, and Clinac 21EX. The 
similar acceptable dose delivery can be achieved in all 3 treatment 
plans. In clinical use, treatment time and image-guided accuracy may 
be the other issues to be considered for higher precision radiotherapy.  
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Purpose/Objective: On-board cone beam CT (CBCT) makes it possible 
to adaptively modify the patient's treatment plan with consideration 
of organ deformation and delivered doses. The CBCT images from the 
Elekta Synergy system have shown large deviations in CT number and, 
as are sult, an elaborate correction strategy is required. In this study, 
for direct dose recomputation on the CBCT images, we were 
developed multi-region histograms methods and investigated the 
potential impact of an integrated procedure for CBCT-based adaptive 
prostate IMRT treatment. 
Materials and Methods: Incase of ten prostate IMRT treatment, 
patient anatomy (prostate, rectum,bladder, etc.) were outlined using 
simulation CT (sim-CT, GE Optima CT 660Pro). Over the treatment 
course of each patient, the CBCT were acquired using ELECTA Synergy 
prior to treatment. The CBCTs were registered to the sim-CTusing a 
deformable algorism and patient anatomy outlined on the sim-CT was 
auto/manual-mapped to the CBCTs (Velocity AI). Then, the HU-D 
table for CBCT was generated by the relative electron densities using 
our methods (in-house program). The cumulative and delivered dose 
of CBCTs obtained using the patient treatment plan. To assess 
adaptive approach for IMRT, the dose delivery history of patient 
anatomy reconstructed after each CBCT was used to analyze 
statistically the confidence interval.  
Results: The max dose, D99 and D95 of cumulative dose for the 
prostate, the proximal and the distal seminal vesicles were small 
difference about ± 2.0%. It is possible that the difference of the 
middle cumulative dose could be more than 2%, but the ?nal 
cumulative dose is still within 2%. The R65 and R40 of the rectum 
were large difference more than 17.0%, 10.0%, respectively. 
Moreover, the B65 andB40 of the bladder were large difference about 
10.0%, 20.0%, respectively. The differences between the cumulative 
and initial plan doses for the OARs were different for each case. The 
PTV margin is commonly used to account for the a geographic miss. In 
this study, with the PTV margins used in current prostate IMRT, the 
dose to the rectum and bladder were large difference while 
maintaining target coverage.Therefore, if the integrated procedure 
methods of the adaptive prostate IMRT treatment of image guidance 
and evaluation of dose using the CBCT are appropriate, the PTV 
margin might be to eliminate. Thereby, the dose to the rectum and 
bladder might be reduced. Moreover, our study suggested that 
correcting the patient's daily setup is often not enough for the OARs 
because of organs deformation. Therefore, accounting for the organ 
deformation is important, especially if the target margin is to be 
reduced for dose escalation. 
Conclusions: Adaptive therapy based on the volumetric on-board CT 
imaging and patient treatment history is an effective way to deliver 
highly conformal IMRT dose to prostate patients on a routine basis. 
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Purpose/Objective: Helical tomotherapy (HT) has been recommended 
as a suitable radiotherapy procedure for breast cancer patients with 
involvement of the supraclavicular nodes (Goddu et al. 2009, Ashenafi 
et al. 2010). The spillover of low doses on non-target organs may 
represents a high risk factor for secondary cancer induction and thus 
the biggest limitation in tomotherapy. Recently, TomoDirect (TD), a 
tomotherapy mode using discrete delivery angles, has been proposed 
as a valid alternative to the helical approach (Jones et. al 2012), 
because it reduces the doses released to the organs at risk (OARs) and 
improves the irradiation treatment time. The reduction in the number 
of fields for tomodirect improves the control of low doses. The 
present work aimed to evaluate the benefits of TD versus HT. 
Materials and Methods: Four cases were selected as representative 
for right or left target as for thin or thick breast shapes. Each case 
was separately planned using helical and direct modalities, prescribing 
50 Gy delivered in 25 fractions to the PTVs. All plans were optimized 
with 2.5 cm jaws and pitch of 0.25 for TD and 0.287 for HT. TD 
planning was performed by selecting 7 fixed fields: 2 tangential fields 
on the breast (PTV1) and 5 fields on the mammary nodes (PTV2). For 
each TD plan the beamlet entrance to the controlateral breast was 
blocked and a dummy organ in the junction area was defined to 
reduce the hotspots and to control the local dose. Dose homogeneity 
was evaluated by the uniformity index (UI) of D5/D95. Comparison 
between direct and helical planning was performed by the evaluation 
of dose volume histogram parameters for PTVs, ipsilateral and 
contralateral lung, contralateral breast and heart, as shown in Table 
1.  
Results: All the organs received doses well below the tolerance levels 
and the PTV coverage and UI resulted equivalent in both the 
approaches (Table 1). High target dose homogeneity was achieved 
with TD on both PTV1 (1.07) and PTV2 (1.03). A significant reduction 
(p<0.05) was observed in the volumes receiving low doses in ipsilateral 
lung (V5(%) decreased from 53.4% in HT to 25.3% in TD, V10(%) from 
29.2% in HT to 17.6% in TD), heart (V5(%) from 71.1% in HT to 4.8% in 
TD) and body (V5(%) from 31.5% in HT to 15.7% in TD). A significant 
increase was found in the volumes with high doses in the ipsilateral 
lung (V40(%) raised from 0.5% in HT to 3.8% in TD), while no significant 
differences were observed for the remaining parameters investigated. 
Treatment duration time in HT (11.9 ± 1.2 min) was comparable with 
TD (11.3 ± 2.2 min). 
 
 
Conclusions: When compared to HT, TD can provide a significant 
reduction of low doses for heart, ipsilateral lung and body, with 
equivalent high homogeneity target coverage. Further, it ensures a 
complete PTV1 irradiation by opening 3 leafs in the air for the 
tangential fields, avoiding target missing for respiratory motion.  
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